Novartis Names New Japan Unit Head Amid Drug Investigation

Novartis announced changes to the senior management of its unit in Japan and also placed a hold on all its clinical trials there while it investigates allegations of questionable activities by some staff with regard to clinical trials, including a protocol breach of a Japanese study of its leukemia drug Tasigna (nilotinib). The drugmaker named Dirk Kosche, who heads emerging growth markets for Novartis Oncology, to replace Yoshiyasu Ninomiya at the helm of the Japanese subsidiary. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments